Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | APAF1 | O14727 | 1/20 | 0.37 |
| ▸ | CPA3 | P15088 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6065012 | 0.82 | LMNA (0.41) | TSHRHDAC1HDAC6ALDH1A1LMNA | |
| SCHEMBL11185212 | 0.82 | LMNA (0.41) | TSHRHDAC1HDAC6ALDH1A1LMNA | |
| SCHEMBL28287517 | 0.81 | LMNA (0.40) | TSHRHDAC1HDAC6ALDH1A1LMNA | |
| SCHEMBL28286182 | 0.81 | LMNA (0.40) | TSHRHDAC1HDAC6ALDH1A1LMNA | |
| SCHEMBL28286136 | 0.81 | NR4A2 (0.41) | TSHRHDAC1HDAC6ALDH1A1HPGD | |
| SCHEMBL6512684 | 0.78 | CTRB1 (0.42) | CTRB1TSHRALDH1A1HPGDKMT2A | |
| SCHEMBL10941926 | 0.78 | CTRB1 (0.42) | CTRB1TSHRALDH1A1HPGDKMT2A | |
| SCHEMBL28583428 | 0.76 | CTRB1 (0.42) | CTRB1HDAC1HDAC6ALDH1A1HPGD | |
| SCHEMBL28583425 | 0.76 | CTRB1 (0.42) | CTRB1HDAC1HDAC6ALDH1A1HPGD | |
| SCHEMBL2326683 | 0.76 | MLYCD (0.44) | CTRB1TSHRALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992169-B2 | Carrier based drug delivery system | CYCLACEL LIMITED (GB) | 2006-01-31 | — | — | US | claimed |
| EP-1093383-B1 | DRUG DELIVERY SYSTEM COMPRISING A HOMEOBOX PEPTIDE AND A CYTOTOXIC OR ANTINEOPLASTIC DRUG | CYCLACEL LTD (GB) | 2004-10-13 | — | — | EP | claimed |
| US-20030119735-A1 | Drug moiety linked to a carrier moiety comprising a homeobox peptide or a fragment or derivative thereof. | CYCLACEL LIMITED OF UNITED KINGDOM | 2003-06-26 | — | — | US | claimed |
| US-6472507-B1 | Carrier based drug delivery system | CYCLACEL LIMITED (GB) | 2002-10-29 | — | — | US | claimed |
| EP-1093383-A1 | DRUG DELIVERY SYSTEM COMPRISING A HOMEOBOX PEPTIDE | Cyclacel Limited (GB) | 2001-04-25 | — | — | EP | claimed |
| WO-2000001417-A1 | DELIVERY SYSTEM | CYCLACEL LIMITED (GB) | 2000-01-13 | — | — | WO | claimed |
| US-7259140-B2 | Heparin-binding peptides and uses thereof | THOMAS JEFFERSON UNIVERSITY (US) | 2007-08-21 | — | — | US | disclosed |
| US-20060172931-A1 | Heparin-binding peptides and uses thereof | THOMAS JEFFERSON UNIVERSITY (US) | 2006-08-03 | — | — | US | disclosed |
| US-6992169-B2 | Carrier based drug delivery system | CYCLACEL LIMITED (GB) | 2006-01-31 | — | — | US | disclosed |
| WO-2005014619-A2 | HEPARIN-BINDING PEPTIDES AND USES THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2005-02-17 | — | — | WO | disclosed |
| EP-1093383-B1 | DRUG DELIVERY SYSTEM COMPRISING A HOMEOBOX PEPTIDE AND A CYTOTOXIC OR ANTINEOPLASTIC DRUG | CYCLACEL LTD (GB) | 2004-10-13 | — | — | EP | disclosed |
| US-20030119735-A1 | Drug moiety linked to a carrier moiety comprising a homeobox peptide or a fragment or derivative thereof. | CYCLACEL LIMITED OF UNITED KINGDOM | 2003-06-26 | — | — | US | disclosed |
| US-6472507-B1 | Carrier based drug delivery system | CYCLACEL LIMITED (GB) | 2002-10-29 | — | — | US | disclosed |
| EP-1093383-A1 | DRUG DELIVERY SYSTEM COMPRISING A HOMEOBOX PEPTIDE | Cyclacel Limited (GB) | 2001-04-25 | — | — | EP | disclosed |
| WO-2000001417-A1 | DELIVERY SYSTEM | CYCLACEL LIMITED (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172931-A1 | Heparin-binding peptides and uses thereof | HRH3, HRH4, SRRM2 | CTRB1 32/4885TSHR 744/4885HDAC1 1801/4885 |
| US-20030119735-A1 | Drug moiety linked to a carrier moiety comprising a homeobox peptide or a fragment or derivative thereof. | CDYL, CDYL2, DAXX | CTRB1 1907/4885TSHR 1010/4885HDAC1 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.